Investment Intelligence. Reimagined.
Listing data synced 2026-04-16. This is the listing record date, separate from quote updates.
Loading SEC business and financials…
Loading views…
Loading your outlook…
Loading…
Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.
Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy. Our lead clinical program is botensilimab (“BOT” or “AGEN1181”), alone and in combination with balstilimab (“BAL”). We also maintain select clinical-stage immuno-oncology assets, which may be used as standalone agents or be complimentary to botensilimab plus balstilimab (“BOT/BAL”).
Excerpt from Item 1 — Business; filed 2026-03-16. May be shortened.
Source: SEC Company Facts. Checked 2026-10-15. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.
Showing a previously fetched snapshot. A recent refresh has not completed.
Biotechnology · US-listed · 10 companies in the recorded group
Same-market companies with the same recorded industry role. Coverage is partial; this is not a full-industry ranking.
Values in USD
Market caps are estimates based on cached closing prices and disclosed share counts.